Figures & data
Figure 1. Protocol steps for pharmacologic MPI SPECT test.
Table 1. Laboratories’ profile characteristics.
Table 2. Comparison of total time from patient admission to patient home readiness/leaving lab (Step A) between stress agents—regadenoson and adenosine.
Table 3. Comparison of total time from patient admission to patient home readiness/leaving lab (Step A) between stress agents—regadenoson and dipyridamole.
Table 4. Comparison in time (min) for each MPI protocol step between stress agents—regadenoson and adenosine.
Table 5. Comparison in time (min) for each MPI protocol step between stress agents—regadenoson and dipyridamole.
Figure 2. Average cumulative time (min) spent directly conducting one MPI test per step by tests using regadenoson, adenosine, and dipyridamole.
Figure 3. Average time spent directly conducting one MPI test by individual laboratory personnel.
Table 6. Time (in min) per patient, per event to manage the reported stress agent-related adverse events (AEs) between regadenoson and adenosine patients.
Table 7. Time (in min) per patient, per event to manage stress agent-related adverse events (AEs) between regadenoson and dipyridamole patients.
Table 8. Estimated number of weekly MPI tests based on laboratory characteristics.
Figure 4. Ranking properties of an ideal MPI stress agent.
